clinical trial · NCT07594847
A Study of HDM1002 Tablets on Cardiac Repolarization in Healthy Subjects
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·phase1·recruiting·n = 72
Healthy Adult SubjectHDM1002 200 mgHDM1002 400 mgPlaceboMoxifloxacin 400 mg
brief summary
The aim of this trial is to evaluate the effect of a single oral dose of HDM1002 tablets on the QT/QTc interval in healthy subjects.
started
Mar 7, 2026
primary completion
Sep 25, 2026
completion
Nov 6, 2026
last updated
May 19, 2026
official title
A Phase I, Single-center, Randomized, Double-blind, Placebo- and Positive-controlled, Four-period, Crossover Clinical Study to Evaluate the Effect of HDM1002 Tablets on Cardiac Repolarization in Healthy Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol